Q: Hi, Are there any estimates available for Covalan ? What should we look for in the upcoming results ? Thanks
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Your opinion please on cardiol therapeutics,crdl.
Q: Can you provide an update on RHT? It seems to have found a technical bottom since november and has made 3 successive higher lows as it moves up and down. What are the fundamentals like? How much of the fundamental strength that you initially saw still exists? Is this a dead (patient home monitoring type) company or just one that you lost patience with and could/should still go. I admit not to have looked into them beyond your recommendation so a summary of their potential catalysts and pitfalls over the next year would be amazing. Take a couple credits if needed to provide a full and thorough answer please.
Thanks
Thanks
Q: What would be a proper weighting in a growth and income portfolio with this news??
Thx
Thx
Q: Is this company worth taking a look at ?
Q: Follow up.....is it better to just sell and wait to re-enter when things get better? Are you planning in taking it out of the portfolio?
Thx!
Thx!
Q: Do you see any reason for the large decrease in share
price for Reliq after naming an advisory board ?
price for Reliq after naming an advisory board ?
Q: Hi Team,
Could I have your opinion on why GUD has been down lately?
Is it based on a news or data ? or just a sentiment? Is it a good time to buy?
Thanks!
Could I have your opinion on why GUD has been down lately?
Is it based on a news or data ? or just a sentiment? Is it a good time to buy?
Thanks!
Q: I’d like to buy a Pharmaceutical company outside the USA.Would Novartis fit the bill or do you prefer another company?
Q: Why is CVS down after their earnings beat ?
Q: Is there a "reason " behind SIS announcing its preliminary and un audited year end and last quarter financial results suddenly , which it had never done in the past ? The figures were not that bad when compared to street estmates, though EBITDA was marginally lower . Is something "brewing " for SIS which an ordinary investor is unaware?
Q: What are your thoughts on SIS's premature earnings release with disappointing EBITDA miss and lowered guidance? Also they pointed to less acquisitions and more focusing on getting the house in order. Obviously not good to hear they are struggling in Europe. I have always liked this mgmt and I feel they handled this primarily negative release well and I appreciate their transparency and guidance on how they plan to fix the issues. But what does this mean for a company that has struggled for the last 5 months, are we now looking at another year plus of lowered guidance, less or no acquisitions, restructuring, and beaten down share price? Thanks
Q: Hi 5i team,
Your comments please on the preliminary unaudited results for Q4 & full year 2018. Would this news change in any way your confidence in the company?
Thanks!
Silvia
Your comments please on the preliminary unaudited results for Q4 & full year 2018. Would this news change in any way your confidence in the company?
Thanks!
Silvia
Q: Knight has been in my portfolio for two years, I've been buying on the dips with an average cost of 7.80$. Should I remain patient or move on. Lots of opportunity out there. Please recommend some alternatives that I may consider should I decide to sell.
Q: Simple question
Does 5i view this deal as significant in any way (from the Globe)
Knight Therapeutics Inc. (GUD-T) announced the closing of a strategic financing agreement in Moksha8 Inc., a specialty pharmaceutical company focused on licensing and marketing “innovative and established therapeutics” in Latin America, for up to US$125-million.
Under the agreement, Knight will initially lend Moksha8 up to US$25-million in working capital funding, of which US$10-million will be issued at closing. Knight said it may issue up to an additional US$100-million in funding for M&A and the acquisition of new licenses.
Does 5i view this deal as significant in any way (from the Globe)
Knight Therapeutics Inc. (GUD-T) announced the closing of a strategic financing agreement in Moksha8 Inc., a specialty pharmaceutical company focused on licensing and marketing “innovative and established therapeutics” in Latin America, for up to US$125-million.
Under the agreement, Knight will initially lend Moksha8 up to US$25-million in working capital funding, of which US$10-million will be issued at closing. Knight said it may issue up to an additional US$100-million in funding for M&A and the acquisition of new licenses.
Q: Good morning,
News on RHT? Do they report at the end of the month?
KC
News on RHT? Do they report at the end of the month?
KC
Q: Could you give your analysis of SUPN. Is it a buy now? Thanks
Q: Hello team,
What is wrong with FDA wanting to review CorMedix's "full data set including secondary endpoints from the LOCK-IT-100 study to facilitate FDA's consideration of CorMedix's request to file the New Drug Application (NDA) for Neutrolin on the basis of the LOCK-IT-100 study results."
Why the 27% drop after the meeting with FDA and willingness of the company to provide the data and fully cooperate?
Hold, Sell, or Average down on CRMD?
Thanks as always.
What is wrong with FDA wanting to review CorMedix's "full data set including secondary endpoints from the LOCK-IT-100 study to facilitate FDA's consideration of CorMedix's request to file the New Drug Application (NDA) for Neutrolin on the basis of the LOCK-IT-100 study results."
Why the 27% drop after the meeting with FDA and willingness of the company to provide the data and fully cooperate?
Hold, Sell, or Average down on CRMD?
Thanks as always.
Q: would appreciate your comments for: Kinross and Prometic
ed
ed
Q: First I want to just thank-you for making me a better investor not just with your recommendations but with your approach. Covalon has. in Appendix B of their annual statement included the notice of the change of auditors. The 'resignation' of BDO is, as it turns out, at the request of Covalon. We are also informed (elsewhere) that there will be no vote on the financial statement. I have gone through about as many of their recent Sedar filings as I can take and perhaps I am reaching here, but is this normal practice to you? Any red flags?